RxDoctor Payments Data

Ahmed Alsadek, MD

Internal Medicine · Fountain Valley, CANPI 1528097730

Payments from drug & device makers

$1,841in general payments, 2019–2025

Across 45 payments — averaging $40.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • USWM, LLC$903
  • Exact Sciences$139
  • MDD US Operations, LLC$129
  • Boston Scientific$122
  • Takeda Pharmaceuticals U.S.A., Inc.$119
  • Lilly USA, LLC$114
  • plus $315 from 7 others

What the payments were for

  • Food & beverage$1,33472%
  • Gifts$50628%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,841 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$22,685
Medicare patients
35
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$45,702
OzempicSemaglutide36$40,646
JanuviaSitagliptin Phosphate40$37,745
XifaxanRifaximin12$36,059
MounjaroTirzepatide21$20,802
JardianceEmpagliflozin19$18,138
LinzessLinaclotide21$14,993
BrilintaTicagrelor12$5,063
BreynaBudesonide/Formoterol Fumarate23$4,624
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,766
Tamsulosin Hcl87$1,505
Rosuvastatin Calcium70$1,041
Fluticasone Propionate93$1,039
Losartan Potassium137$920
Levocetirizine Dihydrochloride12$917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$45,70239 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$100$36,05912 claims
Lilly USA, LLCMounjaro$114$20,80221 claims
Boehringer IngelheimJardiance$26$18,13819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →